Poster Awards, worth €250 each, are awarded to the eight best posters (four clinical and four basic) on display at the annual European Congress of Endocrinology (ECE).
There is no application process. The top 15 clinical and 15 basic science/translational posters are reviewed by members of the ECE Programme Organising Committee (POC) during the congress.
-
The applicant will be the presenting author of the poster during ECE.
-
The applicant must be a current member of ESE and be within 10 years post-PhD or MD.
The eight awarded posters, 4 clinical and 4 basic science/translational, are selected from the top 15 clinical and 15 basic science/translational poster abstracts which attained the best ratings during the abstract evaluation process, based on the scientific content. During the congress, additional assessment will be made on the quality of the poster presentation. The Poster Awards are bestowed by the Programme Organising Committee (POC) to the presenting author of the eight selected posters.
Please note – it is not possible to be awarded both a Poster Award and a People’s Choice Award. The POC’s decision is final.
2025 Winners (Joint Congress ESPE and ESE)
In May 2025, we held a Joint Congress of ESPE and ESE 'Connecting Endocrinology Across the Life Course'. Further information on the Joint Abstract Awards can be found on the Joint Congress 2025 website.
- Mohamed Abubaker, United Kingdom: P10 Validation of prognostic biomarkers in adrenocortical carcinoma through a next generation sequencing in real-life setting.
-
Merisa Abusdal, Norway: P24 The roles of PDLIM1 in silent corticotroph adenomas aggressiveness
-
Corin Badiu, Romania: P3 Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)
-
Felix Chelslin, Sweden: P15 Differential expression and protein abundance of key regulators of the IGF, adiponectin and PPAR signalling pathways in placentas from small, adequate and large for gestational age newborns.
-
Nathalie Erpelding, United States of America: P22 48-Week Results from the HELIOS Trial: A Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Wolfram Syndrome
-
Isabel Viola Frielitz-Wagner, Germany: P8 Diabetes type 1 can induce testicular atrophy with Leydig cell hyperplasia and germ cell depletion and therefore negatively influence reproductive function in rats
-
Laura Lucaccioni, Italy: P14 Impact of early-life exposure to phthalates on anogenital distances in a cohort of healthy children and their mothers, from birth to three years of age.
-
Malene Asp Bock Mejdahl, Denmark: P26 Reproductive hormones in infertile men with Y chromosome microdeletions
-
Sema Okutan, Denmark: P1 Stimulated peak cortisol in healthy participants measured during the insulin tolerance test: defining cut-off limits for adrenal insufficiency with two generations of Roche cortisol immunoassays
-
Luigi Picaro, United Kingdom: P4 Consistent Reduction in Rate of Fracture with Setrusumab Therapy in Patients with Osteogenesis Imperfecta: Month 14 Data from Phase 2 of the Orbit Study
-
Philippa Prentice, United Kingdom: P6 Parathyroid surgery in children with Sporadic and Familial Hyperparathyroidism
-
Mercedes Rivera Cuello, Spain: P20 Setmelanotide in the Management of Pediatric Obesity Due to Genetic Disorders: Clinical Response and Quality of Life Assessment
-
Patrice Rodien, France: P29 THRIVE-2 Phase 3 Trial of Veligrotug (VRDN-001) in Chronic Thyroid Eye Disease (TED): Efficacy and Safety at 15 Weeks
-
Carin Skogastierna, Sweden: P17 Early life growth is important for pubertal growth and adult height
-
Lorenzo Tucci, Italy: P12 Measurement of circulating cell-free DNA concentrations for differential diagnosis of adrenal masses: a pilot study.
-
Yi Wang, China: P23 Genetic basis of patients with congenital gonadotropin deficiency